Study characteristics of included preclinical studies of T-VEC
| Preclinical study | Treatment | Total number of animals used | Type of cancer/model | Efficacy measures* | Risk of bias (/9†) |
| Liu et al 20 | T-VEC; HSV1 wild type immunisation | 90 | Lymphoma (A20 murine lymphoma mouse model) | CR: 100% (n=10) (injected) | 9 |
| Piasecki et al 21 | T-VEC | NR | Lymphoma (A20 murine lymphoma mouse model) | CR: 70%–100% of injected, 50%–60% of contralateral | 9 |
| Piasecki et al 23 | T-VEC +Anti-PD-1 | NR | Colorectal (MC-38 colon carcinoma mouse model) | CR: 80.0% (44.2%–96.5%) (injected) n=10 CR: 20.0% (3.5%–55.8%) (contralateral) n=10 | 9 |
| Cooke et al 22 | T-VEC | 40 | Lymphoma (A20 murine lymphoma mouse model) | CR: 100% (65.5%–100%) (injected) n=10 CR: 50% (23.7%–76.3%) (contralateral) | 9 |
| Cooke et al 24 | T-VEC | 20 | Melanoma (B16F10 melanoma model) | NR: statistically significant tumour reduction and survival noted | 9 |
* DR – durable response; OR – objective response; CR – complete response/complete regression; PR – partial response;DR/OR/CR/PR definitions were based on RECIST guidelines for clinical studies. † Total number of domains that were assessed a score of high risk or unclear (maximum = 9).
CR, complete response; HSV, Herpes Simplex Virus; NR, Not reported; PR, partial response; T-VEC, talimogene laherparepvec.